Breast cancer is traditionally classified by immunohistochemistry into three clinical subtypes: hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2−), HER2+, and triple-negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and breast cancer.